Serum Neurofilament Light Chain and Cardiovascular Outcomes in Patients With Atrial Fibrillation.
A blood-based neurological marker helps identify atrial fibrillation patients at highest cardiovascular risk, expanding tools for personalized risk assessment.
This JAMA Cardiology study identifies serum neurofilament light chain as a novel independent predictor of cardiovascular outcomes in atrial fibrillation patients, translating a neurological biomarker into cardiovascular risk stratification. The finding could expand the prognostic toolkit for AFib management beyond traditional cardiac biomarkers.
What the study was
- Study design
- Prospective cohort study (biomarker analysis)
- Population
- Patients with atrial fibrillation
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- JAMA Cardiology
Why it surfaced
JAMA Cardiology publication; neurofilament light chain in cardiovascular context is genuinely novel (crosses neurological and cardiovascular biomarker disciplines); prospective cohort design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.